Stock Track | Corcept Therapeutics Plummets 5.03% as Full-Year and Q4 Earnings Disappoint

Stock Track03-04

Corcept Therapeutics (NASDAQ:CORT) stock plunged 5.03% in the intraday session on Tuesday, following the company's disappointing financial results for the full year 2024 and the fourth quarter.

For the full year 2024, Corcept reported revenue of $675.0 million, missing analyst estimates by 2.6%. Moreover, the company's earnings per share (EPS) of $1.35 fell short of analyst expectations by 13%, further exacerbating investor concerns.

The company's fourth-quarter performance was also lackluster, with revenue and EPS missing analyst estimates. Corcept's revenue of $181.9 million for the quarter was 8.5% below analysts' expectations, while its EPS figures were significantly below consensus estimates.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157114218?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-05 04:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157114218","market":"hk","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Plummets 5.03% as Full-Year and Q4 Earnings Disappoint","media":"Stock Track","content":"<p>Corcept Therapeutics (NASDAQ:CORT) stock plunged 5.03% in the intraday session on Tuesday, following the company's disappointing financial results for the full year 2024 and the fourth quarter.</p>\n\n<p>For the full year 2024, Corcept reported revenue of $675.0 million, missing analyst estimates by 2.6%. Moreover, the company's earnings per share (EPS) of $1.35 fell short of analyst expectations by 13%, further exacerbating investor concerns.</p>\n\n<p>The company's fourth-quarter performance was also lackluster, with revenue and EPS missing analyst estimates. Corcept's revenue of $181.9 million for the quarter was 8.5% below analysts' expectations, while its EPS figures were significantly below consensus estimates.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Plummets 5.03% as Full-Year and Q4 Earnings Disappoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Plummets 5.03% as Full-Year and Q4 Earnings Disappoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 04:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corcept Therapeutics (NASDAQ:CORT) stock plunged 5.03% in the intraday session on Tuesday, following the company's disappointing financial results for the full year 2024 and the fourth quarter.</p>\n\n<p>For the full year 2024, Corcept reported revenue of $675.0 million, missing analyst estimates by 2.6%. Moreover, the company's earnings per share (EPS) of $1.35 fell short of analyst expectations by 13%, further exacerbating investor concerns.</p>\n\n<p>The company's fourth-quarter performance was also lackluster, with revenue and EPS missing analyst estimates. Corcept's revenue of $181.9 million for the quarter was 8.5% below analysts' expectations, while its EPS figures were significantly below consensus estimates.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1157114218","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157114218","pubTimestamp":1741121558,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corcept Therapeutics  stock plunged 5.03% in the intraday session on Tuesday, following the company's disappointing financial results for the full year 2024 and the fourth quarter.For the full year 2024, Corcept reported revenue of $675.0 million, missing analyst estimates by 2.6%. Moreover, the company's earnings per share  of $1.35 fell short of analyst expectations by 13%, further exacerbating investor concerns.The company's fourth-quarter performance was also lackluster, with revenue and EPS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"Corcept Therapeutics全年和第四季度盈利令人失望，股价暴跌5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics (NASDAQ:CORT) stock plunged 5.03% in the intraday session on Tuesday, following the company's disappointing financial results for the full year 2024 and the fourth quarter.\nFor the full year 2024, Corcept reported revenue of $675.0 million, missing analyst estimates by 2.6%. Moreover, the company's earnings per share (EPS) of $1.35 fell short of analyst expectations by 13%, further exacerbating investor concerns.\nThe company's fourth-quarter performance was also lackluster, with revenue and EPS missing analyst estimates. Corcept's revenue of $181.9 million for the quarter was 8.5% below analysts' expectations, while its EPS figures were significantly below consensus estimates.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157114218"}